https://www.selleckchem.com/products/abt-199.html
6 [95% confidence interval 0.2 to 11.3] percentage points, p=0.04). Microvascular obstruction was less extensive in the tocilizumab arm, but there was no significant difference in the final infarct size between the tocilizumab arm and the placebo arm (7.2% vs. 9.1% of myocardial volume, p=0.08). Adverse events were evenly distributed across the treatment groups. Tocilizumab increased myocardial salvage in patients with acute STEMI. (ASSessing the effect of Anti-IL-6 treatment in Myocardial Infarction [ASSAIL-MI]; NCT03004703). Tocilizum
Like
Comment
Share
